Donnie Holden, MD
Psychiatry · Bentonville, ARNPI 1891880373
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,960 of the $26,256 with a category attached, or 60.8%. 26 manufacturers reported payments, led by AbbVie at 42.0% of the total. Reporting peaked in 2019 at $14,822 and has fallen 97.0% since, to $452 in 2025. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $78.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Alkermes, Inc.$9K
- Neuronetics, Inc.$890
- Johnson & Johnson$872
- Teva Pharmaceuticals USA, Inc.$816
- Otsuka America Pharmaceutical, Inc.$807
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$15,96061%
- Travel & lodging$2,2549%
- Food & beverage$7,70729%
- Education$3341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $11,019 |
| Alkermes, Inc. | 40 | $8,688 |
| Neuronetics, Inc. | 4 | $890 |
| Johnson & Johnson | 19 | $872 |
| Teva Pharmaceuticals USA, Inc. | 18 | $816 |
| Otsuka America Pharmaceutical, Inc. | 26 | $807 |
| Sunovion Pharmaceuticals Inc. | 24 | $656 |
| Vanda Pharmaceuticals Inc. | 21 | $449 |
| Eisai Inc. | 14 | $252 |
| Merck | 14 | $250 |
| Indivior Inc. | 13 | $229 |
| Idorsia Pharmaceuticals US Inc | 4 | $225 |
| Corium, LLC | 7 | $141 |
| Supernus Pharmaceuticals, Inc. | 3 | $140 |
| Lundbeck LLC | 7 | $123 |
| Neurocrine Biosciences, Inc. | 1 | $112 |
| Axsome Therapeutics, Inc. | 1 | $109 |
| Avanir Pharmaceuticals, Inc. | 6 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 4 | $66 |
| Vertical Pharmaceuticals, LLC | 3 | $55 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Harmony Biosciences LLC | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$7,658
- VRAYLAR$6,160
- UBRELVY$3,893
- NEUROSTAR TMS THERAPY SYSTEM$863
- LYBALVI$400
- INVEGA SUSTENNA$257
- SPRAVATO$253
- REXULTI$247
- LATUDA$238
- Austedo XR$235
- INVEGA TRINZA$122
- Dayvigo$117
- INGREZZA$112
- QUVIVIQ$110
- QELBREE$110
- Fanapt$109
- Auvelity$109
- AUSTEDO$100
How this compares
$26,256 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 16 | $31,705 |
| SpravatoEsketamine Hcl | 27 | $27,435 |
| UbrelvyUbrogepant | 11 | $24,032 |
| TrintellixVortioxetine Hydrobromide | 34 | $19,140 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $9,062 |
| LinzessLinaclotide | 12 | $7,405 |
| Protriptyline Hcl | 11 | $6,834 |
| EliquisApixaban | 12 | $6,795 |
| Clonazepam | 550 | $6,150 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $5,821 |
| Lurasidone Hcl | 12 | $5,363 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,313 |
| Lisdexamfetamine Dimesylate | 19 | $4,515 |
| Paliperidone ErPaliperidone | 26 | $3,610 |
| Meprobamate | 11 | $2,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Linzess, Armour Thyroid | $11,019 | $32,23138 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $807 | $31,70516 claims |
| Johnson & JohnsonSpravato | $872 | $27,43527 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $75 | $24,45248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Bentonville
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Ronald WautersSearcy$204K
- Herman ClementsSearcy$187K
- Randal ScholmaLowell$111K
- Kyle JohnsonMorrilton$69K
- Paul WylieLittle Rock$54K
- Angela ChapmanFayetteville$40K
- Joann KirchnerNorth Little Rock$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.